Company: CMND
Filing Date: 2025-02-04
Form Type: 6-K
Source: 0001213900-25-010066
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-02-04
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: February 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

Attached hereto and incorporated
herein is the Registrant’s press release issued on February 4, 2025, titled “Clearmind Medicine Announces Publication of Patent
for Binge Behavior Psychedelic Combination Treatment in Mexico”.

The first two paragraphs of
the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements
on Form F-3 (File Nos.333-275991, 333-270859, 333-273293) and Form S-8
(File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.

<div align='center'>1

EXHIBIT INDEX</div>

| Exhibit No. |     |                                                                                                                                           |
| 99.1        |     | Press release titled: “Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico” |

<div align='center'>2

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

| Date: February 4, 2025 | Clearmind Medicine, Inc. 
 (Registrant)             
 By:                      | /s/ Adi Zuloff-Shani    |
|:-----------------------|:-------------------------|:------------------------|
|